ITI Pharma and Healthcare Fund Direct Growth NAV today
AMFI: 149268ISIN: INF00XX01BO9MUTF_IN: ITI_PHAR_AND_1OU61PQITI Mutual FundSectoral / Thematic funds
NAV ₹18.9865up ₹0.37 (2.00%)
NAV for 27 Oct 2026, against 26 Oct 2026. Declared once a day.
Other plans: Regular IDCW ₹17.2087 · Regular Growth ₹17.2087, 2.00% · Direct IDCW ₹18.9843
- Fund sizeAssets under management. The money the fund manages for all its investors, across every plan, at the end of the month. Assets under management in the glossary
- ₹266 CrSep 2026
- Expense ratioTotal expense ratio. What the fund charges each year as a share of the money invested, taken out of the NAV every day, so the returns shown are already after it. Total expense ratio: how it is worked out
- 0.89%26 Oct 2026
- Exit loadExit load. A charge, as a share of the amount redeemed, on units sold before a set period has passed since they were bought. Exit load in the glossary
- 0.50%if sold within 3 months
- P/EP/E. What the fund pays for each rupee of yearly profit its companies earn: the total value of its shares divided by those companies' last four quarters of profit, each in proportion to what the fund holds. The profit leaves out one-off items (exceptional items and businesses sold or demerged), so one company's one-off gain cannot pull the fund's P/E down. A loss-making company lowers the profit. Shown when at least 80% of the fund's shares are counted. P/E in the glossary
- 45.430 Sep 2026
- Risk levelRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month. Riskometer in the glossary
- Very HighAug 2026
- HoldingsHoldings. The number of different securities in the fund's latest monthly portfolio: shares, bonds, money market paper and units of other funds, not cash, overnight lending or futures. Holdings in the glossary
- 3730 Sep 2026
- LaunchedLaunch date. The day the fund first allotted units to investors, at the close of its new fund offer. Launch date in the glossary
- 8 Nov 2021
ITI Pharma and Healthcare Fund returns
Direct Growth plan
Over each window to 27 Oct 2026
| Over | Direct GrowthTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). Trailing return: how it is worked out | Regular Growth | BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back. Benchmark in the glossary | Rank in categoryRank in category. The fund's place among the funds of its category with a return over the same window, highest return first. Rank in category in the glossary | Category medianCategory median. The middle return of the funds in the category over the same window: half returned more, half less. Category median in the glossary | Middle halfMiddle half of the category. The returns of the fund a quarter of the way down the category and the fund a quarter of the way up, over the same window: half the category's funds returned between the two. Middle half of the category in the glossary |
|---|---|---|---|---|---|---|
| 1 week | +2.13% | +2.10% | +2.31% | – | – | – |
| 1 month | −5.54% | −5.68% | −4.56% | 166 of 254 | −5.09% | −6.1% to −3.8% |
| 3 months | −2.35% | −2.77% | −3.35% | 60 of 250 | −5.24% | −7.1% to −2.5% |
| 6 months | +9.06% | +8.14% | +6.99% | 42 of 250 | −1.83% | −5.2% to +4.8% |
| 1 year | +6.93% | +5.03% | +7.63% | 41 of 229 | −3.87% | −8.7% to +2.9% |
| 3 years | +19.44% | +17.25% | +20.40% | 23 of 141 | +13.05% | +9.0% to +17.8% |
| 5 years | Needs 5 years | – | – | – | +10.66% | +8.0% to +14.9% |
| 10 years | Needs 10 years | – | – | – | +14.11% | +11.9% to +15.7% |
₹10,000 put in on 11 Nov 2021 is ₹18,976 at the NAV of 27 Oct 2026Growth of ₹10,000. What ₹10,000 put in at the NAV of the first day would be worth at the latest NAV, after the fund's expenses and before tax and any exit load. Growth of ₹10,000 in the glossaryOver a year and longer, a return is the yearly rate. Benchmark: NIFTY Healthcare TRI, over the same days as the fund. Rank, median and middle half among the Direct plans of Sectoral / Thematic funds, each fund's return to its latest NAV on or before 27 Oct 2026.
At the month end, 30 Sep 2026
| Over | Fund | BenchmarkBenchmark return. The change in the benchmark index's total return level over the same dates as the fund's return, as a yearly rate over a year and longer. Benchmark return in the glossary |
|---|---|---|
| 1 year | +13.88% | +14.70% |
| 3 years | +18.92% | +19.04% |
| Since launch | +14.57% | +14.37% |
Benchmark: NIFTY Healthcare TRI. Both as the fund house states them for the month.
Return in each calendar year
- Fund, Direct GrowthCalendar year return. The change in NAV from the last NAV of one year to the last NAV of the next.
- NIFTY Healthcare TRI
- Loss
Highest year to Dec 2024, +44.0%; lowest year to Dec 2025, −8.2%Above the benchmark in 3 of 4 years
ITI Pharma and Healthcare Fund SIP returns
₹10,000 on the 1st of every month, valued at the NAV of 27 Oct 2026SIP calculator
| Period | InvestedAmount invested. ₹10,000 on the 1st of every month, or the next day the fund priced, added up over the period. Amount invested in the glossary | Value todayValue today. What the units bought by every instalment are worth at the latest NAV. Value today in the glossary | Invested against value today | SIP returnSIP return (XIRR). The yearly rate that, applied to each monthly instalment from the day it was invested, gives the value of all the units today. SIP return (XIRR) in the glossary | After stamp dutySIP return after stamp duty. The same SIP return with stamp duty of 0.005% taken from every instalment since 1 Jul 2020, so ₹10,000 buys ₹9,999.50 of units. SIP return after stamp duty in the glossary | Stamp dutyStamp duty paid. The stamp duty on all the instalments, in rupees: 0.005% of each purchase made since 1 Jul 2020. Stamp duty paid in the glossary |
|---|---|---|---|---|---|---|
| 1 year12 instalments | ₹1,20,000 | ₹1,27,628₹1,27,622 after stamp duty | +12.27% | +12.26% | ₹6 | |
| 3 years36 instalments | ₹3,60,000 | ₹4,19,308₹4,19,287 after stamp duty | +10.24% | +10.23% | ₹18 | |
| Since Nov 202159 instalments | ₹5,90,000 | ₹8,66,260₹8,66,216 after stamp duty | +15.70% | +15.70% | ₹30 |
5 years: Launched 8 Nov 2021, needs 5 years of history.
A SIP that rises every year: Step-up SIP calculator
Rolling returns
Per cent a year, every window from 11 Nov 2021 to 27 Oct 2026
Lowest to highestAverage
LowestLowest rolling return. The lowest yearly return of any window of this length in the fund's history, one window starting on each day it priced. Lowest rolling return in the glossaryAverageAverage rolling return. The average of the yearly returns of every window of this length in the fund's history. Average rolling return in the glossaryHighestHighest rolling return. The highest yearly return of any window of this length in the fund's history. Highest rolling return in the glossaryEnded higherWindows that ended higher. The share of all the windows of this length in which the NAV ended above where it started. Windows that ended higher in the glossary
1 year975 windows−9.3%+19.0%+62.0%77.9%
3 years484 windows+17.3%+21.7%+26.9%100.0%
5 yearsLaunched 8 Nov 2021, needs 6 years of history
Every 3-year window ended higher than it started.
ITI Pharma and Healthcare Fund expense ratio and exit load
Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.
- Regular over directDirect and regular plan cost gap. The regular plan's expense ratio less the direct plan's: what buying through a distributor costs each year, since both plans own the same portfolio. Direct and regular plan cost gap in the glossary
- 1.70 ptsA year, on 26 Oct 2026
- Direct, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies. Expense ratio, 30-day average in the glossary
- 0.89%Over the last 30 days filed
- Regular, 30-day average
- 2.59%Over the last 30 days filed
Total expense ratio, month by month
- Regular plan
- Direct plan
Direct plan highest 3.11%, Apr 2026.Direct plan lowest 0.29%, Feb 2022.
What the expense ratio is made of
| Part | Direct | Regular |
|---|---|---|
| Base expense ratioBase expense ratio. The part of the expense ratio that pays the fund house and the distributor, before brokerage, transaction costs, levies and GST. Base expense ratio in the glossary | 0.58% | 2.10% |
| Brokerage | 0.07% | 0.07% |
| Transaction costs | None | None |
| Statutory levies | 0.24% | 0.42% |
Per cent of assets a year, filed for 26 Oct 2026. The parts add up to that day's total.
Exit load, in the fund house's words
If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL
Buying and selling
- Lump-sum purchases
- Accepted
- Minimum investmentMinimum investment. The smallest amount the plan accepts for a first purchase. Minimum investment in the glossary
- ₹5,000
- Minimum top-up
- ₹1,000
- Minimum redemption
- ₹1
- SIP
- Accepted
- SIP instalments, at least
- Daily- 30 ; Weekly/Monthly -12 or 6
- STP, transfers to another fund
- Not accepted
- SWP, regular withdrawals
- Accepted
- Switches
- Accepted
- Lock-inLock-in. The time after each purchase during which those units cannot be sold. Lock-in in the glossary
- None
- SIP minimum
- Daily: Rs. 500/-/ Weekly and Monthly:Rs. 500/- or Rs. 1000/
- SIP dates
- Daily (Every Business Day), Weekly (Any Day from Monday to Friday),Monthly (Every Business Day)
As listed for this plan on 28 Oct 2026.
How ITI Pharma and Healthcare Fund is taxed
Taxed as an equity fund where it keeps 65% or more in shares of listed Indian companies: gains on units held over 12 months are taxed at 12.5% above ₹1.25 lakh a year, and gains on units held 12 months or less at 20%. Otherwise, gains on units held over 24 months are taxed at 12.5%, and gains on units held 24 months or less at the income tax slab rate.
IDCW payouts are added to the holder's income and taxed at the income tax slab rate. The fund deducts 10% tax at source for a resident when its payouts to them in a year counted from April to March are above ₹10,000.
Rules in force from 1 Apr 2025, checked 27 Oct 2026. Surcharge and cess are not included.
ITI Pharma and Healthcare Fund AUM
₹ crore, every plan of the fund together.
- Average assetsAverage assets under management. The money the fund managed, averaged over every day of the quarter, added up across its plans.
- ₹266 CrQuarter to Sep 2026
- In the direct plansShare of assets in the direct plans. The direct plans' average assets for the quarter as a percentage of the fund's total; the rest is in the regular plans, bought through distributors. Share of assets in the direct plans in the glossary
- 8.1%Of the quarter's average
Average assets by quarter, by plan
- Regular plans
- Direct plans
The latest quarter is the largest since the quarter to Dec 2021.
Assets at each month end
Highest ₹276 Cr, Aug 2026.Lowest ₹129 Cr, Oct 2023.
ITI Pharma and Healthcare Fund portfolio
Portfolio disclosed for 30 Sep 2026.
Holdings on 30 Sep 2026
| Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month. Large, mid and small cap in the glossary | Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. Weight in the fund in the glossary | Held since. The first month end of the fund's current run of holding this position; marked "or earlier" where that month is the fund's first portfolio on record or the first after a gap in its portfolios. Held since in the glossary | |||
|---|---|---|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | Large cap13th | 11.96% | 31.82 | 1,75,147 | Nov 2021or earlier |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | Large cap50th | 9.51% | 25.30 | 27,227 | Mar 2022 |
| Apollo Hospitals EnterpriseHealthcare Services | Large cap97th | 5.45% | 14.49 | 17,745 | Dec 2022 |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | Mid cap104th | 4.78% | 12.72 | 1,03,145 | Mar 2022 |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | Large cap61st | 4.78% | 12.71 | 26,473 | Oct 2024 |
| Max Healthcare InstituteHealthcare Services | Mid cap111th | 4.49% | 11.93 | 1,28,340 | Nov 2021or earlier |
| CiplaPharmaceuticals & Biotechnology | Large cap99th | 4.19% | 11.14 | 82,778 | Mar 2022 |
| Laurus LabsPharmaceuticals & Biotechnology | Mid cap171st | 4.02% | 10.70 | 54,023 | Mar 2025 |
| Aurobindo PharmaPharmaceuticals & Biotechnology | Mid cap138th | 4.01% | 10.68 | 63,858 | Aug 2023 |
| Mankind PharmaPharmaceuticals & Biotechnology | Mid cap119th | 3.78% | 10.05 | 40,139 | May 2023 |
| Cohance LifesciencesPharmaceuticals & Biotechnology | Small cap428th | 3.14% | 8.34 | 1,87,861 | Nov 2021or earlier |
| Alkem LaboratoriesPharmaceuticals & Biotechnology | Mid cap164th | 3.09% | 8.22 | 15,912 | Jun 2024 |
| Neuland LaboratoriesPharmaceuticals & Biotechnology | Small cap356th | 3.07% | 8.16 | 3,820 | Oct 2024 |
| Global HealthHealthcare Services | Small cap262nd | 2.85% | 7.59 | 55,636 | Jun 2026 |
| Fortis HealthcareHealthcare Services | Mid cap156th | 2.77% | 7.37 | 95,763 | Jan 2022 |
Weight is per cent of the fund's net assets; value in ₹ crore.
Cash and receivables on 30 Sep 2026
| Net Receivables / (Payables) | 0.69% | 1.88 |
Weight is per cent of the fund's net assets; value in ₹ crore.
- Largest holdingLargest holding. The share of the fund in its single largest position, cash and futures not counted as positions. Largest holding in the glossary
- 11.96%Sun Pharmaceutical Industries
- Top 5 holdingsTop 5 holdings. The share of the fund held in its five largest positions. Top 5 holdings in the glossary
- 36.48%
- Top 10 holdingsTop 10 holdings. The share of the fund held in its ten largest positions. Top 10 holdings in the glossary
- 56.97%
- Effective holdingsEffective number of holdings. The number of equal-sized positions that would be as concentrated as the fund's actual weights. Effective number of holdings in the glossary
- 20.7Taken over 99.31% of the fund
Asset allocation
Asset allocation. What the fund owns, by kind of asset, each as a share of its net assets; futures and options are shown beside it, not in it, since they are contracts rather than assets bought. Asset allocation in the glossary- Indian shares99.31%
- Cash and receivables0.69%
Per cent of the fund's net assets.
Large, mid and small cap
- Large cap36.14%Category 49.50%
- Mid cap40.73%Category 21.62%
- Small cap23.13%Category 26.68%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026. Category is the average of 249 Sectoral / Thematic funds.
Sector allocation
Sector weight. The fund's shares grouped by the business each company is in, less the futures sold on them, each group as a share of the fund's net assets. Sector weight in the glossary3sectors
- Healthcare97.17%Category 12.70%
- Consumer Durables1.22%Category 3.48%
- Chemicals0.92%Category 1.97%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026. Category is the average of 254 Sectoral / Thematic funds. Category average. The sector's weight, less the futures sold on it, averaged over the 254 Sectoral / Thematic funds that disclosed a portfolio for Sep 2026. A fund holding none of the sector counts as 0.
Sector allocation month by month
| 13 months | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare35 companies | 97.17% | 97.03% | 93.06% | 92.31% | 91.57% | 92.13% | 92.34% | 91.49% | 93.39% | 93.05% | 92.94% | 93.13% | |
| Consumer Durables1 company | 1.22% | 1.25% | 1.23% | 1.22% | 1.47% | 1.29% | 1.11% | 0.99% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Chemicals1 company | 0.92% | 0.99% | 1.10% | 1.25% | 2.42% | 2.65% | 3.66% | 3.46% | 2.54% | 2.45% | 2.12% | 2.88% | |
| Financial Services | 0.00% | 0.00% | 0.46% | 0.51% | 1.73% | 1.26% | 1.25% | 1.36% | 1.41% | 1.35% | 1.26% | 1.25% | |
| Capital Goods | 0.00% | 0.00% | 1.16% | 1.49% | 0.81% | 0.91% | 0.82% | 0.92% | 0.90% | 1.04% | 0.97% | 1.05% | |
| Automobile And Auto Components | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Consumer Services | 0.00% | 0.00% | 0.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Information Technology | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Fast Moving Consumer Goods | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Oil Gas & Consumable Fuels | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Telecommunication | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Power | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Per cent of the fund's net assets, less the futures sold on its shares, at each month end, Oct 2025 to Sep 2026; the line runs from Sep 2025.
Bought and sold
Sep 2026 against Aug 2026, position by position.
Positions changed, month by month
- New
- Added
- Trimmed
- Sold out
- New positionsNew positions. Holdings in this month's portfolio that were not in the month before. New positions in the glossary
- 11.03% of the fund
- Sold outSold out. Holdings in last month's portfolio that are gone from this one, other than a bond or deposit repaid on its due date. Sold out in the glossary
- 11.05% of the fund before
- Added toAdded to. Holdings with more units than the month before. Where the fund states no units, a weight that rose by more than a tenth. Added to in the glossary
- 8
- TrimmedTrimmed. Holdings with fewer units than the month before. Where the fund states no units, a weight that fell by more than a tenth. Trimmed in the glossary
- 5
- UnchangedUnchanged. Holdings with the same number of units as the month before. Their weight can still move with the price. Unchanged in the glossary
- 23
- Traded at leastTraded at least. The smaller of the weight bought in new positions and the weight sold out of old ones, cash left out: the least the fund must have bought and sold in the month. Traded at least in the glossary
- 1.03%
- Weight that movedWeight that moved. Half the sum of every position's change in weight between the two month ends, new and sold positions included; price moves alone raise it. Weight that moved in the glossary
- 3.49%
Changes in Sep 2026
| What changed. New: not held the month before. Added or trimmed: more or fewer units than the month before, or, where no units are stated, a weight that moved by more than a tenth. Sold out: held the month before, gone now. Matured: a bond or deposit whose repayment date fell between the two portfolios, so it was repaid rather than sold (one sold in its last days reads the same). What changed in the glossary | Change in weight. The holding's weight this month less its weight the month before, in percentage points; a price move alone changes it. Change in weight in the glossary | ||||
|---|---|---|---|---|---|
| Thyrocare Technologies | Sold out | – | 1.05% | −1.05 pts | −48,000 |
| Gland Pharma | New | 1.03% | 0.00% | +1.03 pts | +9,443 |
| Mankind Pharma | Added | 3.78% | 3.31% | +0.47 pts | +2,297 |
| Lupin | Trimmed | 2.04% | 2.43% | −0.39 pts | −3,929 |
| Divi's Laboratories | Added | 9.51% | 9.23% | +0.28 pts | +291 |
| Sai Life Sciences | Added | 1.87% | 1.59% | +0.28 pts | +2,445 |
| Alkem Laboratories | Added | 3.09% | 2.92% | +0.17 pts | +786 |
| Aster DM Quality Care | Added | 1.59% | 1.47% | +0.12 pts | +7,323 |
| Linde India | Trimmed | 0.92% | 0.99% | −0.07 pts | −426 |
| Rainbow Childrens Medicare | Added | 1.00% | 0.93% | +0.07 pts | +1,997 |
| Fortis Healthcare | Added | 2.77% | 2.82% | −0.05 pts | +9,725 |
| Piramal Pharma | Trimmed | 1.27% | 1.32% | −0.05 pts | −6,263 |
| Torrent Pharmaceuticals | Added | 4.78% | 4.75% | +0.03 pts | +554 |
| Shilpa Medicare | Trimmed | 1.61% | 1.59% | +0.02 pts | −5,309 |
| Laurus Labs | Trimmed | 4.02% | 4.02% | 0.00 pts | −3,994 |
Weights are per cent of the fund's net assets; a change in weight is in percentage points.
Holdings month by month
| Holding | Oct 25 | Nov 25 | Dec 25 | Jan 26 | Feb 26 | Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries | 10.96% | 12.73%Added | 10.91%Cut | 10.76% | 11.12% | 11.80% | 12.40%Added | 14.25%Added | 13.34%Cut | 13.26%Cut | 12.58% | 11.96% |
 Divi's Laboratories | 8.97% | 8.75%Added | 8.90% | 8.96% | 9.01% | 8.77% | 8.83% | 8.43%Cut | 6.79%Cut | 7.97% | 9.23%Added | 9.51%Added |
 Apollo Hospitals Enterprise | 6.35%Added | 6.12% | 5.91%Cut | 6.21% | 6.62% | 6.60% | 6.25% | 6.20%Cut | 6.22% | 6.05%Cut | 5.72% | 5.45% |
 Dr. Reddy's Laboratories | 2.57%Added | 1.72%Cut | 1.79% | 1.83% | 1.83% | 1.87% | 1.82% | 3.98%Added | 5.44%Added | 4.41% | 4.31%Added | 4.78% |
 Torrent Pharmaceuticals | 4.51%Added | 4.26%Cut | 4.55% | 4.98% | 5.17% | 5.28% | 4.82% | 4.90% | 4.56%Cut | 4.84% | 4.75%Added | 4.78%Added |
 Max Healthcare Institute | 5.71% | 6.08%Added | 5.64% | 5.49% | 5.94% | 5.50% | 5.22% | 4.90% | 5.41% | 5.05% | 4.84%Added | 4.49% |
 Cipla | 3.07%Added | 1.91%Cut | 1.94% | 1.81% | 1.75% | 1.67% | 1.64% | 3.42%Added | 4.60%Added | 4.43% | 4.22%Added | 4.19% |
 Laurus Labs | 1.69%Added | 1.85% | 2.05% | 1.90% | 2.01% | 3.65%Added | 4.24%Added | 5.06% | 4.40%Cut | 4.21%Cut | 4.02%Cut | 4.02%Cut |
 Aurobindo Pharma | 3.70% | 4.02% | 4.00% | 4.55%Added | 4.45%Added | 4.99% | 4.36%Cut | 4.28%Cut | 4.10%Cut | 3.84%Cut | 3.97% | 4.01% |
 Mankind Pharma | 1.22%Cut | 1.71%Added | 1.72% | 1.97%Added | 1.98% | 1.85% | 1.91% | 1.95% | 2.84%Added | 3.39%Added | 3.31%Added | 3.78%Added |
 Cohance Lifesciences | 4.43%Added | 3.58%Added | 3.45% | 2.65% | 2.04% | 2.09% | 3.08% | 2.65% | 2.89%Added | 3.04%Added | 3.10% | 3.14% |
 Alkem Laboratories | 2.95% | 3.07% | 3.06% | 3.36% | 3.17% | 3.12% | 2.93% | 2.88% | 2.75% | 2.92%Added | 2.92%Added | 3.09%Added |
 Neuland Laboratories | 2.82% | 2.98% | 2.79%Added | 2.65%Added | 2.70%Added | 2.66% | 3.05% | 3.00%Cut | 3.09% | 3.03% | 3.18%Cut | 3.07% |
 Global Health | – | – | – | – | – | – | – | – | 2.01%Bought | 2.98%Added | 2.98% | 2.85% |
 Fortis Healthcare | 3.98%Cut | 3.60% | 3.58% | 3.66% | 3.85% | 2.91%Cut | 3.11% | 3.02% | 2.94% | 2.79% | 2.82%Added | 2.77%Added |
Per cent of the fund's net assets at each month end, Oct 2025 to Sep 2026. Under it, the change on the fund's previous month. "After a gap" is a holding after a month with no portfolio on record, so when it was bought is not known; "Not filed" is one gone across such a gap.
Risk ratios
NAV to 27 Oct 2026
Each bar runs from the lowest to the highest figure among the Direct plans of Sectoral / Thematic funds (130 funds) over the same 3 years; the tick is their average and the dot this fund.
How much the NAV moves
Standard deviationStandard deviation. How far the fund's monthly returns spread around their average, stated as a yearly figure: the wider the spread, the more the NAV moves. Standard deviation in the glossary16.76%
12.76%Lowest17.49%Average of 138 funds31.25%Highest
Downside deviationDownside deviation. Standard deviation counting only the months in which the fund lost money, stated as a yearly figure. Downside deviation in the glossary9.59%
5.67%Lowest10.73%Average of 138 funds16.26%Highest
Sharpe ratioSharpe ratio. The monthly return above the 91-day Treasury bill yield, divided by its standard deviation and stated for a year: the extra return for each unit of movement in the NAV. Sharpe ratio in the glossary0.77
−0.56Lowest0.47Average of 138 funds1.19Highest
Sortino ratioSortino ratio. The monthly return above the 91-day Treasury bill yield, divided by how far it fell below that yield and stated for a year: the extra return for each unit of movement on the way down. Sortino ratio in the glossary1.24
−0.68Lowest0.75Average of 138 funds2.32Highest
Against NIFTY Healthcare TRI
BetaBeta. How much the fund's monthly return moved for each 1% move in its benchmark: 1 moves with it, below 1 moves less. Beta in the glossary0.95
0.63Lowest0.93Average1.21Highest
AlphaAlpha. The yearly return the fund made beyond what its beta to the benchmark accounts for. Alpha in the glossary+0.54 pts
−6.37 ptsLowest+1.93 ptsAverage of 93 funds+12.46 ptsHighest
R-squaredR-squared. The share of the fund's monthly movement that its benchmark's movement explains, from 0 to 100. R-squared in the glossary90.6
42.9Lowest87.3Average98.2Highest
CorrelationCorrelation. How closely the fund's monthly returns moved in step with its benchmark's, from minus 1 (always opposite) to 1 (always together). Correlation in the glossary0.95
0.66Lowest0.93Average0.99Highest
Upside captureUpside capture. The fund's return in the months its benchmark rose, as a percentage of the benchmark's return in those months. Upside capture in the glossary94.0%
65.5%Lowest99.0%Average134.6%Highest
Downside captureDownside capture. The fund's return in the months its benchmark fell, as a percentage of the benchmark's fall in those months. Downside capture in the glossary87.8%
45.6%Lowest87.9%Average118.1%Highest
Information ratioInformation ratio. The fund's return above its benchmark, divided by how much that difference varied, as stated by the fund house. Information ratio in the glossaryTo 30 Sep 2026−0.03
Largest falls
| Largest over | FallLargest fall. The biggest drop in NAV from a high to the low that followed, before the NAV went back above that high. Largest fall in the glossary | High on | Low on | Back at the highBack at the high. The first day the NAV closed at or above the high it had fallen from. Back at the high in the glossary |
|---|---|---|---|---|
| 1 year | −11.70% | 3 Nov 2025 | 29 Jan 2026 | 6 May 2026 |
| 3 years | −17.07% | 2 Jan 2025 | 3 Mar 2025 | 24 Jun 2026 |
| Since Nov 2021 | −17.69% | 13 Jan 2022 | 17 Jun 2022 | 16 Jun 2023 |
Risk level by month
| Months | Fund | BenchmarkBenchmark's risk level. The riskometer level of the fund's benchmark index for the same month, on the same six-step scale as the fund's own. Benchmark's risk level in the glossary |
|---|---|---|
| Oct 2022 to Aug 202647 months | Very High | Very HighNIFTY Healthcare TRI |
The riskometer at each month end, the fund's and its benchmark's. A month with none on record is left out.
ITI Pharma and Healthcare Fund managers
Managers now
| Manager | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. Return in the manager's time in the glossary | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. Benchmark over the same days in the glossary | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. Difference from the benchmark in the glossary | Portfolio changed after the handover. How much of the portfolio was different three months after the manager took over: half the sum of every holding's change in weight, with each side's holdings scaled to add up to 100 so a move into cash does not count. Portfolio changed after the handover in the glossary | Portfolio changed before the handover. The same measure over the three months before the manager took over, since portfolios change anyway. Portfolio changed before the handover in the glossary | Assets the manager runs. The latest monthly size of every fund the manager runs now, added up; a fund run with others counts in full for each of its managers, and the line under it counts only the funds they run alone. Assets the manager runs in the glossary | ||
|---|---|---|---|---|---|---|---|---|
| Animesh SinghFund manager | May 2026 | +2.30%over 171 days | +1.87% | +0.43 pts | 15.0% | 10.7% | 5 | ₹1,362 Cr |
| Nilay DalalFund Manager | May 2026 | +2.30%over 171 days | +1.87% | +0.43 pts | 15.0% | 10.7% | 9 | ₹4,186 Cr |
Returns are the direct plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.
Other funds they run
| Fund | |||||
|---|---|---|---|---|---|
| ITI Banking and Financial Services FundAnimesh Singh | May 2026 | −6.54%over 171 days | −5.24% | −1.29 pts | ₹362 Cr |
| ITI Bharat Consumption FundAnimesh Singh | May 2026 | −1.04%over 171 days | −6.58% | +5.53 pts | ₹350 Cr |
| ITI Balanced Advantage FundAnimesh Singh | May 2026 | −4.88%over 171 days | – | – | ₹320 Cr |
| ITI Flexi Cap FundNilay Dalal | May 2026 | +3.08%over 171 days | −5.92% | +9.00 pts | ₹1,588 Cr |
| ITI Large & Midcap FundNilay Dalal | May 2026 | −3.39%over 171 days | −6.81% | +3.42 pts | ₹691 Cr |
| ITI Banking and Financial Services FundNilay Dalal | May 2023 | +10.93%a year | +8.66% | +2.27 pts | ₹362 Cr |
| ITI Large Cap FundNilay Dalal | May 2026 | −3.50%over 171 days | −5.36% | +1.86 pts | ₹352 Cr |
| ITI Value FundNilay Dalal | May 2026 | −9.53%over 171 days | −5.92% | −3.62 pts | ₹346 Cr |
| ITI Balanced Advantage FundNilay Dalal | May 2026 | −4.88%over 171 days | – | – | ₹320 Cr |
| ITI Multi Asset Allocation FundNilay Dalal | Sep 2026 | −5.04%over 46 days | – | – | ₹144 Cr |
The ten largest by assets, by manager. Returns are the direct plan's.
Portfolio overlap
Funds holding the most of the same securities, by weight.
Closest funds in the category
| Portfolio overlap. The share of the two funds' portfolios that is the same: for every holding they share, the smaller of its two weights, added up. Portfolio overlap in the glossary | Shared holdings. The number of securities both funds hold, cash and futures left out. Shared holdings in the glossary | |
|---|---|---|
| Mirae Asset Healthcare FundMirae Asset Mutual Fund | 66.88% | 20 |
| SBI Healthcare Opportunities FundSBI Mutual Fund | 61.79% | 22 |
| LIC MF Healthcare FundLIC Mutual Fund | 60.16% | 20 |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 59.58% | 22 |
| Bajaj Finserv Healthcare FundBajaj Finserv Mutual Fund | 58.68% | 19 |
| Nippon India Pharma FundNippon India Mutual Fund | 57.57% | 20 |
| Aditya Birla Sun Life Pharma and Healthcare FundAditya Birla Sun Life Mutual Fund | 54.46% | 23 |
| Bandhan Healthcare FundBandhan Mutual Fund | 54.09% | 20 |
| Baroda BNP Paribas Health and Wellness FundBaroda BNP Paribas Mutual Fund | 54.03% | 19 |
| Tata India Pharma & Healthcare FundTata Mutual Fund | 53.71% | 21 |
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.
Overlap with the fund house's other funds
| ITI Business Cycle FundITI Mutual Fund | 14.24% |
| ITI Mid Cap FundITI Mutual Fund | 10.72% |
| ITI Small Cap FundITI Mutual Fund | 9.15% |
| ITI Large & Midcap FundITI Mutual Fund | 8.83% |
| ITI Multi Cap FundITI Mutual Fund | 7.50% |
| ITI Value FundITI Mutual Fund | 7.06% |
| ITI Focused FundITI Mutual Fund | 5.96% |
| ITI Large Cap FundITI Mutual Fund | 5.32% |
| ITI Flexi Cap FundITI Mutual Fund | 5.20% |
| ITI Bharat Consumption FundITI Mutual Fund | 5.10% |
As the fund house states it, for Sep 2026.
Changes to the fund
Newest first.
2026
- 1 AprExpenseExpense ratio stated under the new rules: a base ratio, with brokerage, levies and GST on top
Fund details
Objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Asset allocation
- Equity, Units issued by REITs & Equity related instruments of companies engaged in pharma and healthcare 80%-100%, Equity, Units issued by REITs and Equity related securities of other Companies 0%-20%, Listed Preference Shares 0%-10%, Debt and Money Market Instruments 0%-20%, Units issued by InvITs 0%-10%
Type of scheme
An open ended Equity scheme investing in Pharma and Healthcare
- Stated category
- Sectoral/Thematic Funds
- Benchmark
- Nifty Healthcare Total Return Index
- Risk level at launch
- Very High risk
- New fund offer
- 18 Oct 2021 to 1 Nov 2021
- Units first allotted
- 8 Nov 2021
- Open for sale again
- 11 Nov 2021
- Price at the offer
- ₹10 a unit
- Minimum at the offer
- ₹5,000
Plans and codes
| Plan | AMFI code | ISIN | ISIN, reinvestment | MUTF_IN | First NAV |
|---|---|---|---|---|---|
| Direct Growth | 149268 | INF00XX01BO9 | ITI_PHAR_AND_1OU61PQ | 11 Nov 2021 | |
| Regular Growth | 149270 | INF00XX01BL5 | ITI_PHAR_AND_MUGBRY | 11 Nov 2021 | |
| Direct IDCW | 149271 | INF00XX01BP6 | INF00XX01BQ4 | ITI_PHAR_AND_15OL2YE | 11 Nov 2021 |
| Regular IDCW | 149269 | INF00XX01BM3 | INF00XX01BN1 | ITI_PHAR_AND_1FLTTLB | 11 Nov 2021 |
This fund
- Scheme information documentThe fund's objective, terms, costs and risks in full
Factsheet
- Factsheet - September 2026ITI Mutual Fund, Sep 2026
Statement of additional information
- SAI ITI Mutual FundITI Mutual Fund, Oct 2026
Annual report
- Abridged Annual Report - ITI Mutual Fund 2025-26ITI Mutual Fund, Mar 2026
- Consolidated Annual Report - ITI Mutual Fund 2025-26ITI Mutual Fund, Mar 2026
Riskometer disclosure
- Disclosure Of Risk-O-Meter Levels FY 2025-26ITI Mutual Fund, Mar 2026
Portfolio overlap disclosure
- Debt Portfolio Overlap - September 2026ITI Mutual Fund, Sep 2026
- Equity Portfolio Overlap - September 2026ITI Mutual Fund, Sep 2026
- Hybrid Portfolio Overlap - September 2026ITI Mutual Fund, Sep 2026